RHY — Rhythm Biosciences Share Price
0.000.00%
Last trade - 00:00- AU$21.55m
- AU$17.26m
- AU$0.05m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.42 | ||
| Price to Tang. Book | 5.37 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 205.58 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -106.89% | ||
| Return on Equity | -71.1% | ||
| Operating Margin | -5037.38% | ||
Financial Summary
| Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 0.05 | 0.01 | 0.02 | 0.23 | 0.05 | n/a | n/a | -18.01% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Rhythm Biosciences Ltd is an Australia-based medical diagnostics company. The Company is engaged in delivering simple, affordable blood tests for accurate and early detection of cancers. It is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer and saving lives. The Company has developed ColoSTAT, a blood test for the detection of Colorectal Cancer (CRC). The ColoSTAT Test-Kit measures five specific protein biomarkers that indicate the likelihood of CRC. The test is an alternative for individuals who are unable or unwilling to participate in current screening programs. It is being updated to meet the IVDR (In vitro diagnostic medical devices regulation) regulatory standards. The Company also offers population level predictive risk testing for a range of cancers and other serious and common diseases.
Directors
- Otto Buttula CHM
- Glenn Gilbert CEO
- Pauline Moffatt SEC
- Adrien Wing SEC
- Trevor Lockett DRC
- Louis Panaccio NED (64)
- Eduardo Vom NED
- Rachel David NID
- Last Annual
- June 30th, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- June 1st, 2017
- Public Since
- December 7th, 2017
- No. of Shareholders
- 4,330
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Australian Stock Exchange - SEATS
- Shares in Issue
- 283,596,750
- Address
- Bio21 Institute, MELBOURNE, 3010
- Web
- https://www.rhythmbio.com/
- Phone
- +61 396140600
- Auditors
- BDO Audit Pty Ltd
Upcoming Events for RHY
Similar to RHY
Actinogen Medical
Australian Stock Exchange - SEATS
Adalta
Australian Stock Exchange - SEATS
Algorae Pharmaceuticals
Australian Stock Exchange - SEATS
Alterity Therapeutics
Australian Stock Exchange - SEATS
Amplia Therapeutics
Australian Stock Exchange - SEATS
FAQ
What is the Rhythm Biosciences share price?
As of Today at 04:55 UTC, shares in Rhythm Biosciences are trading at AU$0.08. This share price information is delayed by 15 minutes.
How has the Rhythm Biosciences share price performed this year?
Shares in Rhythm Biosciences last closed at AU$0.08 and the price had moved by -9.52% over the past 365 days. In terms of relative price strength the Rhythm Biosciences share price has underperformed the ASX All Ordinaries Index by -13.26% over the past year.
What are the analyst and broker recommendations for Rhythm Biosciences?
There is no consensus recommendation for this security.
Find out moreWhat is the Rhythm Biosciences dividend yield?
Rhythm Biosciences does not currently pay a dividend.
Does Rhythm Biosciences pay a dividend?
Rhythm Biosciences does not currently pay a dividend.
When does Rhythm Biosciences next pay dividends?
Rhythm Biosciences does not currently pay a dividend.
How do I buy Rhythm Biosciences shares?
To buy shares in Rhythm Biosciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Rhythm Biosciences?
As of the previous close price of AU$0.08, shares in Rhythm Biosciences had a market capitalisation of AU$21.55m.
Where are Rhythm Biosciences shares listed?
Here are the trading details for Rhythm Biosciences:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: RHY
What kind of share is Rhythm Biosciences?
Based on an overall assessment of its quality, value and momentum Rhythm Biosciences is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Rhythm Biosciences share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Rhythm Biosciences share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Rhythm Biosciences. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -21.18%.
As of the last closing price of AU$0.08, shares in Rhythm Biosciences were trading -7.56% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Rhythm Biosciences PE Ratio?
The Rhythm Biosciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.08.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Rhythm Biosciences?
Rhythm Biosciences' management team is headed by:
- Otto Buttula - CHM
- Glenn Gilbert - CEO
- Pauline Moffatt - SEC
- Adrien Wing - SEC
- Trevor Lockett - DRC
- Louis Panaccio - NED
- Eduardo Vom - NED
- Rachel David - NID